Under pricing pressure, insulin maker joins CVS Reduced Rx savings program

Facing pressure from lawmakers about the prices of their drugs, some pharmaceutical companies are looking for ways to make their products more affordable and more accessible.

Novo Nordisk (NYSE:NVO) said yesterday that it is teaming up with CVS Health‘s (NYSE:CVS) new prescription savings program, Reduced Rx, to offer discounts on its insulin. The company’s insulin will be sold for $25 per 10 milliliter vial, which Nordisk said reflects a savings of as much as $100 for patients that pay with cash.

Get the full story at our sister site, Drug Delivery Business News.

The post Under pricing pressure, insulin maker joins CVS Reduced Rx savings program appeared first on MassDevice.

from MassDevice http://ift.tt/2mXKB6e